Semaglutide vs. Tirzepatide: What Your Clinic Needs to Know

The GLP-1 conversation in weight loss medicine has changed dramatically in the past two years. Where clinics once debated whether to add semaglutide to their formulary, many are now asking a more nuanced question: should we carry semaglutide, tirzepatide, or both — and how do we decide which is right for which patient?

It’s a good problem to have. Both medications represent a genuine leap forward in what medical weight loss can deliver. Clinical trials for semaglutide demonstrated average body weight reductions of approximately 15% over 68 weeks. Tirzepatide’s SURMOUNT-1 trial pushed that further, showing reductions of 20–22% over 72 weeks. For clinic operators, both numbers represent outcomes that create loyal patients and strong word-of-mouth.

Important context: the trial results cited above are from studies of FDA-approved branded medications — Wegovy (semaglutide) and Zepbound (tirzepatide). Compounded versions of these drugs are not FDA-approved and have not been evaluated for safety, effectiveness, or quality. The choice between these medications for a given patient — and the question of whether to offer one or both in your practice — involves more than efficacy data. Regulatory status, compounding availability, patient cost tolerance, side effect profiles, and your clinic’s operational maturity all factor into the decision. This guide walks through everything you need to know before making that call.

Understanding the Mechanism: What Makes Them Different

Both semaglutide and tirzepatide work by mimicking hormones that regulate appetite and blood sugar, but they operate on different receptor pathways — and that distinction explains much of the clinical difference between them.

Semaglutide: GLP-1 Receptor Agonist

Semaglutide binds selectively to the glucagon-like peptide-1 (GLP-1) receptor. GLP-1 is a hormone released after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and — critically for weight loss — signals satiety to the brain. By mimicking this hormone, semaglutide reduces appetite, decreases caloric intake, and promotes sustained weight loss.

Semaglutide was originally developed for type 2 diabetes management (Ozempic) before a higher-dose formulation was approved specifically for chronic weight management (Wegovy) in 2021. The weight loss indication created the foundation for the compounded semaglutide market that emerged when branded supply fell short of demand.

Tirzepatide: Dual GLP-1 + GIP Receptor Agonist

Tirzepatide adds a second mechanism: it also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone that works synergistically with GLP-1 to regulate appetite and energy metabolism. The dual-agonist activity is the primary reason tirzepatide consistently shows higher weight loss efficacy than GLP-1 monotherapy in head-to-head and comparative data.

Tirzepatide was approved for type 2 diabetes as Mounjaro (2022) and for weight management as Zepbound (2023). Compounded tirzepatide became widely available when the branded medication appeared on the FDA drug shortage list, though as with semaglutide, the regulatory landscape around compounding continues to evolve.

At-a-Glance Comparison

Semaglutide

• Mechanism: GLP-1 receptor agonist
• Brand names: Ozempic (diabetes), Wegovy (weight loss)
• FDA approval: Approved for weight loss (Wegovy, 2021)
• Compounded status: Was on shortage list; compounding status evolving
• GI side effects: Nausea, vomiting, constipation (common at titration)
• Cost sensitivity: Generally lower cost at equivalent doses
• Best for: Established first-line GLP-1 program; proven protocols

Tirzepatide

• Mechanism: Dual GLP-1 + GIP receptor agonist
• Brand names: Mounjaro (diabetes), Zepbound (weight loss)
• FDA approval: Approved for weight loss (Zepbound, 2023)
• Compounded status: Currently on shortage list; compounding active
• GI side effects: Similar profile; potentially higher at initiation
• Cost sensitivity: Higher cost; stronger results may justify premium
• Best for: Patients seeking maximum efficacy; prior GLP-1 non-responders

Note: Compounding regulations are subject to change. Verify current status with your compliant supplier before making formulary decisions.

Efficacy: What the Clinical Data Actually Shows

Both medications produce weight loss outcomes that were considered extraordinary by pre-GLP-1 standards. The relevant question for clinic operators isn’t whether they work — they clearly do — it’s understanding the magnitude of difference and what it means for your patient population.

Semaglutide Clinical Outcomes

The landmark STEP 1 trial (semaglutide 2.4 mg weekly) showed an average 14.9% reduction in body weight over 68 weeks in adults with obesity or overweight with a weight-related comorbidity. Approximately 86% of participants achieved at least 5% weight loss, and more than a third lost 20% or more of their body weight. These outcomes, combined with improvements in cardiometabolic markers, established semaglutide as the new benchmark in medical weight management.

Semaglutide’s track record, established clinical protocols, and compounding availability made it the de facto entry point for most weight loss clinics launching GLP-1 programs from 2022 onward. Most providers and patients are more familiar with it, and the body of real-world clinical experience is larger.

Tirzepatide Clinical Outcomes

The SURMOUNT-1 trial evaluated tirzepatide at doses of 5 mg, 10 mg, and 15 mg weekly over 72 weeks. At the highest dose, participants achieved a mean weight reduction of 22.5% — nearly 50% greater than semaglutide’s STEP 1 results. Approximately 57% of participants on the 15 mg dose achieved at least 20% body weight reduction.

It’s worth noting that direct head-to-head trial data between semaglutide and tirzepatide for weight loss specifically is limited — the trials used different populations and designs. The comparative data in diabetes (the SURPASS-CVOT and related trials) consistently favors tirzepatide on both HbA1c reduction and weight loss endpoints, providing strong indirect support for tirzepatide’s superiority in dual-indication patients.

Regulatory and Compounding Status: What Clinic Operators Must Understand

For many weight loss clinics, the practical decision between semaglutide and tirzepatide is significantly shaped by their compounding status — because compounded versions of both medications are substantially more accessible and cost-effective for cash-pay patients than branded alternatives.

Semaglutide Compounding Status

Semaglutide was added to the FDA drug shortage list in 2022, which created the legal basis for 503A and 503B compounding pharmacies to compound the active pharmaceutical ingredient. The FDA has subsequently moved to remove semaglutide from the shortage list, which has created compliance deadlines and enforcement activity targeting compounding operations that do not meet the applicable standards.

For clinic operators, this means the compounded semaglutide landscape is in transition. Clinics relying on compounded semaglutide should be working with compliant suppliers who are actively monitoring the regulatory situation and sourcing from pharmacies with documented 503A or 503B compliance. This is not a space where “good enough” sourcing is acceptable — your prescribing license is on the line.

Tirzepatide Compounding Status

As of this writing, tirzepatide remains on the FDA drug shortage list, meaning 503A and 503B compounding of tirzepatide is currently permitted. This creates an active and accessible market for compounded tirzepatide for weight loss — but clinic operators should be aware that this status is subject to change on the same trajectory semaglutide followed.

The prudent approach is to treat tirzepatide’s compounding availability as a present-day opportunity, not a permanent feature of the landscape. Clinics building tirzepatide programs should document their compliance posture, ensure their supplier is monitoring shortage list status, and have a contingency plan for the branded medication pathway if compounding access narrows.

A Note on Salt Forms

Both compounded semaglutide and tirzepatide are sometimes formulated as salt compounds (semaglutide sodium, tirzepatide acetate, etc.) rather than the base peptide used in branded medications. The FDA has raised specific concerns about salt form compounds, and enforcement posture in this area is evolving. Ensure your supplier can document the exact formulation and its compliance basis before administering to patients.

Side Effect Profiles: Preparing Your Patients

Both medications share a similar gastrointestinal side effect profile, which is the most common reason patients reduce doses or discontinue treatment. Understanding — and proactively managing — these effects is one of the most important aspects of running a successful GLP-1 program.

• Nausea: The most common side effect, particularly during dose escalation. Most patients experience diminishing nausea as they acclimate to each dose level. Setting expectations before titration is critical for retention.

• Vomiting and diarrhea: Less common but reported in a meaningful percentage of patients, particularly at higher doses. Dietary guidance — smaller meals, avoiding high-fat foods at initiation — reduces incidence.
• Constipation: More common than patients expect, and more persistent than nausea in some cases. Preemptive guidance on hydration and fiber intake improves the patient experience significantly.
• Gastroparesis-like symptoms: Slowed gastric emptying can produce bloating, early satiety, and discomfort. Clinically significant gastroparesis is rare but worth monitoring, particularly in patients with pre-existing GI conditions.
• Injection site reactions: Mild and typically transient. Proper injection technique guidance at initiation reduces incidence.

Tirzepatide may produce more pronounced GI symptoms at initiation compared to semaglutide for some patients, likely related to the dual-agonist mechanism and higher absolute potency. This is manageable with slower titration and appropriate patient counseling, but it’s worth setting expectations clearly when transitioning patients from semaglutide or starting de novo on tirzepatide.

Both medications carry a class warning regarding thyroid C-cell tumors based on rodent studies; this is a standard informed consent element. Neither should be used in patients with personal or family history of medullary thyroid carcinoma or MEN2.

Which Medication for Which Patient? A Practical Framework

The good news for clinic operators is that having both options available gives you meaningful clinical flexibility. The choice isn’t always obvious, and in many cases both are reasonable first-line options. The framework below is a practical starting point — not a clinical protocol. Apply your clinical judgment and patient-specific factors in every case.

Consider Semaglutide First If…

• Patient is cost-sensitive or on a fixed income
• Patient has strong insurance coverage for Wegovy
• Clinic is establishing its first GLP-1 protocol
• Patient is GLP-1 naive with moderate weight loss goals
• Regulatory environment in your state favors compounded semaglutide

Consider Tirzepatide First If…

• Patient prioritizes maximum efficacy above cost
• Patient has had inadequate response to GLP-1 monotherapy
• Patient has concurrent type 2 diabetes or insulin resistance
• Patient has significant weight to lose and wants fastest results
• Tirzepatide compounded supply is available and compliant

One practical sequencing strategy many clinics use: start GLP-1 naive patients on semaglutide for the first 12–16 weeks, assess response, and offer tirzepatide as an upgrade pathway for patients who respond but want to accelerate results — or as a rescue option for patients with inadequate response. This approach manages initial cost for patients while preserving tirzepatide as a differentiated offering.

Operational Considerations: Running a Two-Medication GLP-1 Program

Stocking both medications adds operational complexity — but for most clinics beyond the very early stage, the clinical and commercial case for carrying both is strong. Here’s what to plan for:

• Separate informed consent documents: Each medication requires its own consent covering mechanism, expected outcomes, side effects, and the compounding status of the formulation you’re administering. Generic GLP-1 consent is not sufficient.
• Distinct titration protocols: Semaglutide and tirzepatide use different dose escalation schedules and milestones. Staff must be trained on each separately, and your EHR dosing templates should reflect the distinct protocols.
• Cold-chain storage for both: Both medications require refrigerated storage. Ensure your medical refrigerator has adequate capacity and temperature logging for a two-medication inventory.
• Inventory management: With two GLP-1 products, forecasting becomes more important. Track patient panel by medication, anticipate titration-related volume increases, and maintain adequate inventory — running out during a patient’s titration phase is a significant retention risk.
• Patient-facing communication: Patients researching GLP-1 options will come in with opinions and questions. Prepare your team with consistent, accurate talking points on how you decide between the two medications and why the clinic’s approach is clinically grounded.

Sourcing Both Medications: What to Expect From Your Compliant Supplier

Running a two-medication GLP-1 program means your supplier relationship becomes even more consequential. You need a partner who can reliably supply both products, stays ahead of the regulatory landscape on both, and gives you the documentation your compliance posture requires.

• Dual-product supply reliability: Confirm your supplier carries both semaglutide and tirzepatide with consistent availability — not just the more common product. Supply disruptions on one medication when you’ve already transitioned patients to it are operationally and clinically disruptive.
• Proactive regulatory updates: A quality supplier monitors FDA shortage list status, compounding enforcement activity, and salt form guidance on your behalf. You should not be learning about regulatory changes from patients or news articles — your supplier should be keeping you informed.
• Full documentation package: Certificates of Analysis, compounding pharmacy credentials, and formulation documentation for both products. If a supplier can’t produce this readily, that’s your answer about whether to work with them.
• Volume pricing across your full formulary: As you grow patient volume across both medications, your per-unit cost should reflect that. Suppliers who treat each product as an independent pricing relationship are leaving money on the table for you.

NMR Meds supplies both semaglutide and tirzepatide to weight loss clinics and medical spas nationwide, along with complementary products — lipotropic B12, IV therapy, HRT and TRT compounds, and drug screening — from a single account. One supplier, full documentation, nationwide fulfillment.

Frequently Asked Questions

Is tirzepatide better than semaglutide for weight loss?

Clinical trial data consistently shows tirzepatide producing greater average weight loss than semaglutide — approximately 20–22% versus approximately 15% body weight reduction in landmark trials. However, individual patient response varies, and both medications produce outcomes that were considered exceptional by pre-GLP-1 standards. The “better” medication for a given patient depends on their clinical profile, goals, cost tolerance, and how they respond to each agent.

Can patients switch from semaglutide to tirzepatide?

Yes, and many clinics offer tirzepatide as an escalation or rescue option for semaglutide patients who want improved results or had an inadequate response. Transitioning patients should be managed carefully — the dosing milestones are different, and GI side effects may recur during the transition period. Allow appropriate washout time and begin tirzepatide at the starting dose rather than attempting dose equivalence.

Is compounded tirzepatide legal?

As of this writing, tirzepatide remains on the FDA drug shortage list, which creates the legal basis for 503A and 503B compounding pharmacies to compound tirzepatide for weight loss. However, this status is subject to change — as demonstrated by semaglutide’s trajectory — and enforcement of compounding standards is ongoing. Clinics should work with suppliers who document their compliance basis and monitor shortage list status actively.

Should a new weight loss clinic start with semaglutide or tirzepatide?

Most clinics launching a GLP-1 program start with semaglutide: established protocols, larger real-world experience base, and — in many cases — more accessible compounded supply. Tirzepatide is an excellent addition once your program is operational and you’re comfortable managing GLP-1 patients. Starting with both simultaneously adds operational complexity that many early-stage clinics are better positioned to handle after their semaglutide program is running smoothly.

What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy are FDA-approved brand-name drugs containing semaglutide as their active pharmaceutical ingredient: Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly; Wegovy is approved specifically for chronic weight management at up to 2.4 mg weekly. Mounjaro and Zepbound are FDA-approved brand-name drugs containing tirzepatide: Mounjaro for type 2 diabetes; Zepbound for chronic weight management. Compounded semaglutide and compounded tirzepatide are not the same as these FDA-approved products. Compounded drugs are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness, or quality, and are not generic versions of the branded medications.

How do I decide how to price tirzepatide vs. semaglutide in my clinic?

Pricing should reflect your actual cost of goods at your current volume, your desired margin, and your local market’s price sensitivity. Tirzepatide typically carries higher per-unit costs than semaglutide at equivalent doses, which most clinics pass through with a modest premium. Some clinics position tirzepatide explicitly as a premium offering — with corresponding positioning around its superior efficacy data — which can support higher pricing without patient resistance.

Conclusion

The semaglutide vs. tirzepatide question isn’t really a competition — it’s an opportunity. Clinics that understand the clinical distinctions, stay current on the regulatory landscape, and build operational capacity to offer both medications are positioned to serve a broader patient population and deliver stronger outcomes than single-medication programs.

The bottom line: start with semaglutide if you’re building your first GLP-1 program, add tirzepatide as a differentiating option once your protocols are established, and work with a compliant supplier who makes the regulatory and supply side of both products as frictionless as possible.

NMR Meds works with licensed practitioners to provide compounded medications pursuant to patient-specific prescriptions, alongside a full wellness formulary. Visit nmrmeds.com/weight-loss/ to explore our full catalog, or open a provider account to get started.

 

MEDICAL & LEGAL DISCLAIMER